Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;12(6):522-529.
doi: 10.1007/s11899-017-0417-7.

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Nathan Singh  1   2   3 , Junwei Shi  4 , Carl H June  1   3   4   5 , Marco Ruella  6   7   8
Affiliations
Review

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Nathan Singh et al. Curr Hematol Malig Rep. 2017 Dec.

Abstract

Purpose of review: In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy.

Recent findings: Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. As CART19 enters routine clinical use, improving the efficacy of this exciting platform is the next step in broader application. Novel gene-editing technologies like CRISPR-Cas9 allow facile editing of specific genes within the genome, generating a powerful platform to further optimize the activity of engineered T cells.

Keywords: Adoptive cell therapy; CRISPR-Cas9; Chimeric antigen receptor T cells (CART); Gene-editing; Immunotherapy; PD-1; TALEN; Zinc-finger nucleases.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Nathan Singh and Junwei Shi each declare no potential conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. The Journal of experimental medicine. 1955;102(2):157–77. - PMC - PubMed
    1. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957;3(3):241–52. - PubMed
    1. Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M. Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res. 1965;25(9):1525–31. - PubMed
    1. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300(19):1068–73. - PubMed
    1. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991;78(8):2120–30. - PubMed

Publication types